Medication info
Procyta Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Procyta Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
Bright brown, round, biconvex film-coated tablets
Packaging
28 tablets/box [14 tablets/PTP*2]
Approval status
Active

MFDS item code 202101369 · Approved 2021.02.17 · Insurance code 654006080

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (refer to Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medication and periodically thereafter. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone, and in cases where blood sugar control is difficult with monotherapy in patients who have not previously used diabetes medications, it is used in combination with metformin. Additionally, when blood sugar control is insufficient with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can be administered in combination. In cases where complex combination therapy is needed, this medication can also be added to support more effective blood sugar management. Thus, this medication is used to improve blood sugar control at various stages of treatment.

How to take

Adult dose

This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (refer to Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medication and periodically thereafter. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Precautions

This medication may cause rare but serious allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, stop taking it immediately and consult a doctor. During the use of this medication, inflammation of the pancreas, known as pancreatitis, may occur, so if symptoms such as severe abdominal pain or vomiting occur, inform the medical staff immediately. This medication should not be used by patients with type 1 diabetes or diabetic ketoacidosis, and it should not be taken by individuals who are allergic to this drug or any of its ingredients. Patients with impaired kidney function need to adjust the dosage of this medication and should undergo regular kidney function tests. While taking this medication, side effects such as cold symptoms, headache, dyspepsia, and diarrhea may occur, and particularly when taken with insulin or sulfonylureas, hypoglycemic symptoms may occur more frequently, so caution is advised. Symptoms of hypoglycemia include dizziness, trembling, and cold sweats, and it is important to consume sugar immediately and consult with medical staff if these symptoms occur. This medication is not recommended for pregnant or breastfeeding women, and its safety in children or adolescents under 18 years has not been established. Elderly patients may experience reduced kidney function, therefore dosage adjustments and monitoring of kidney function are necessary. In case of overdose, seek medical attention immediately, as this medication can be partially removed by hemodialysis. If symptoms such as joint pain or skin blisters occur during treatment, inform the doctor immediately and discontinue the medication if necessary. Due to the possibility of interactions with other medications, especially if taking insulin, sulfonylureas, cyclosporine, or digoxin, consult medical staff. While this medication does not have a significant impact on the cardiovascular system, it is still important to monitor cardiovascular symptoms during its use.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe pain in joints accompanied by disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, indigestion, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and it is safe to store at room temperature between 1 and 30 degrees Celsius. Therefore, avoid excessively hot or cold places and keep it in an area that maintains an appropriate temperature.

Appearance and packaging

Appearance

Bright brown, round, biconvex film-coated tablets

Package unit

28 tablets/box [14 tablets/PTP*2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.